Investigation of Hypersensitivity Reactions in Carboplatin Desensitization Therapy.

Naoki Shibata, Kazuyoshi Kawakami, Shimizu Hisanori, Kazuo Kobayashi, Mayu Yunokawa, Hiroyuki Kanao, Iori Taki, Remi Murase, Daisuke Kamei, Masakazu Yamaguchi

Anticancer research 2022 Feb

filter terms:

Carboplatin is a key drug in the treatment of ovarian cancer, but hypersensitivity reactions (HSRs) may occur with repeated use. Thirty-seven ovarian cancer patients treated with carboplatin desensitization therapy were reviewed retrospectively. The treatment completion rate and toxicity were examined. The carboplatin desensitization completion rate was 86.5%. Toxicity was Grade 0, 1, 2, and 3 in 17, 5, 10, and 5 patients, respectively. Erythema was the most frequent toxicity (36.8%), most commonly affecting the arm (23.5%). Furthermore, all HSRs were classified into: skin, respiratory, digestive, circulatory, and neurological. The completion rate of desensitization was significantly lower in patients with two or more target organs affected (p<0.001). The main symptoms of HSRs, the most common sites of HSRs, and the criteria for discontinuing desensitization therapy identified in this study are useful information for the safe implementation of carboplatin desensitization therapy. Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Citation

Naoki Shibata, Kazuyoshi Kawakami, Shimizu Hisanori, Kazuo Kobayashi, Mayu Yunokawa, Hiroyuki Kanao, Iori Taki, Remi Murase, Daisuke Kamei, Masakazu Yamaguchi. Investigation of Hypersensitivity Reactions in Carboplatin Desensitization Therapy. Anticancer research. 2022 Feb;42(2):1091-1097